Vanguard Group’s Genprex GNPX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-394
Closed -$73.2K 4357
2025
Q3
$73.2K Buy
394
+380
+2,714% +$95.6K ﹤0.01% 4257
2025
Q2
$3.49K Hold
14
﹤0.01% 4271
2025
Q1
$3.75K Hold
14
﹤0.01% 4276
2024
Q4
$13K Hold
14
﹤0.01% 4277
2024
Q3
$5.54K Hold
14
﹤0.01% 4335
2024
Q2
$28.9K Hold
14
﹤0.01% 4337
2024
Q1
$45.6K Sell
14
-28
-67% -$184K ﹤0.01% 4325
2023
Q4
$420K Hold
42
﹤0.01% 4090
2023
Q3
$721K Hold
42
﹤0.01% 3943
2023
Q2
$1.73M Hold
42
﹤0.01% 3714
2023
Q1
$1.66M Hold
42
﹤0.01% 3742
2022
Q4
$2.65M Buy
42
+1
+2% +$56.5K ﹤0.01% 3561
2022
Q3
$2.57M Hold
41
﹤0.01% 3642
2022
Q2
$2.54M Hold
41
﹤0.01% 3707
2022
Q1
$4.1M Sell
41
-1
-2% -$97.5K ﹤0.01% 3625
2021
Q4
$2.41M Hold
42
﹤0.01% 3973
2021
Q3
$4.96M Hold
42
﹤0.01% 3667
2021
Q2
$6.2M Hold
42
﹤0.01% 3477
2021
Q1
$8.03M Buy
42
+27
+180% +$5.93M ﹤0.01% 3275
2020
Q4
$2.69M Buy
15
+5
+50% +$773K ﹤0.01% 3581
2020
Q3
$1.49M Hold
10
﹤0.01% 3571
2020
Q2
$1.4M Buy
10
+3
+43% +$367K ﹤0.01% 3530
2020
Q1
$734K Buy
+7
New +$720K ﹤0.01% 3579
2019
Q4
Sell
-1
Closed -$28K 4128
2019
Q3
$28K Buy
+1
New +$42.2K ﹤0.01% 4117
2019
Q2
Hold
0
4144
2019
Q1
Hold
0
4093
2018
Q4
Hold
0
4130
2018
Q3
Hold
0
4143
2018
Q2
Hold
0
4065

Other funds holding GNPX

Vanguard Group's GNPX Position: Q4 2025 in Review

Vanguard Group sold out of Genprex (GNPX) in Q4 2025, closing a stake of 394 shares — an estimated $73.2K sold.

Vanguard Group first reported a position in GNPX in Q3 2019 and held it in 24 quarters. The position peaked at $8.03M in Q1 2021. 9 funds tracked by Wall St. Rank hold GNPX as of Q4 2025.

  • Vanguard Group reported no remaining Genprex position as of Q4 2025 after selling out during the quarter.
  • Vanguard Group sold 394 Genprex shares in Q4 2025, an estimated $73.2K.
  • Vanguard Group first reported a position in Genprex in Q3 2019 and held it in 24 quarters.
  • Vanguard Group's Genprex position peaked at $8.03M in Q1 2021.
  • 9 funds tracked by Wall St. Rank held Genprex as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.